Episodes - The Bloodline with Blood Cancer United Podcast

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn’t mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United’s Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.

The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.

Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Astellas Pharma US Inc.; Daiichi Sankyo Inc.; Debiopharm; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Acute Myeloid Leukemia (AML): New Approaches For A Complex Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.

A cancer diagnosis in your 20s or 30s can raise questions most people never expect to face so early in life.

In this episode, we speak with Chris Pagliarulo, who was diagnosed with Hodgkin lymphoma at the age of 29, about the medical, emotional, and practical realities of cancer during early adulthood. We explore issues that are especially relevant for adolescent and young adult (AYA) patients, including delayed diagnosis, fertility preservation, treatment side effects, career disruption, relationships, and finding connection with others who understand. While this conversation highlights experiences unique to AYAs, patients and caregivers of all ages may hear pieces of their own experience reflected in what Chris shares.

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Merck & Co., Inc.

The post A Young Adult Story: Cancer, Connection, and Life After Treatment first appeared on The Bloodline with Blood Cancer United Podcast.

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Syndax Pharmaceuticals Inc.

The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.

The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families.

In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech;  Kite, a Gilead Company; Novartis Pharmaceuticals Corporation.

The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Cutaneous T‑cell lymphoma (CTCL) is a rare condition that often raises important questions for patients and families.

In this episode, we sit down with Dr. Stefan Barta, of the University of Pennsylvania, to bring clarity to what CTCL is, how it’s diagnosed, and what patients can expect from staging and treatment. Dr. Barta breaks down the differences between CTCL subtypes, explains why diagnosing someone can take time, and shares the most up-to-date therapies, including skin directed treatments, immunotherapies, and emerging clinical trial options. Most importantly, he offers reassurance for those newly diagnosed: “The future is absolutely bright… there is a lot of hope for our patients with CTCL.”

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Kyowa Kirin, Inc. and Cutaneous Lymphoma Foundation.

The post Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward first appeared on The Bloodline with Blood Cancer United Podcast.

Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts.

In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it’s treated today, and what researchers are learning about managing side effects.

Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you’re newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what’s on the horizon.

*This is not an official program of the ASH annual meeting

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Geron Corporation and Taiho Oncology, Inc.

The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Ann Grace MacMullan, Director of Integrative Wellness at the International Waldenstrӧm’s Macroglobulinemia Foundation (IWMF), to explore how wellness can become a powerful part of life after a cancer diagnosis. Ann Grace shares practical, calming techniques, including breathing exercises, “Bee’s Breath”, and guided meditation, that you can do anywhere to reduce stress and feel more grounded. We’ll also dive into what integrative wellness really means, why it matters for blood cancer patients, and how concepts like the “self-care sandwich” can help you start and end your day with intention.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Merck & Co., Inc.

The post Hope Meets Healing: Simple Practices for Stress Relief first appeared on The Bloodline with Blood Cancer United Podcast.

Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it’s an umbrella term for multiple subtypes, and what today’s treatments and tomorrow’s innovations could mean for you. From understanding subtypes and staging to exploring options like watchful waiting, chemotherapy, and cutting-edge immunotherapies, we cover what matters most: knowledge, clarity, and hope.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Supported by AbbVie Inc. and Genentech, A Member of the Roche Group.

The post The Big Picture on Non-Hodgkin Lymphoma: Treatments, Trends, and Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.